The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Once-weekly bortezomib dosing as SoC in multiple myeloma: an international survey of physicians
Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, discusses a global online survey of physicians investigating the attitudes and perceptions to dosing of bortezomib in patients with multiple myeloma (MM). Although bortezomib is often dosed twice weekly in trials, this survey found that the majority of MM-treating physicians opt for once-weekly dosing and that this appears to have become the global standard of care (SoC), likely due to exhibiting similar efficacy with less associated peripheral neuropathy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: SparkCures, Janssen, BMS, Genentech, Sanofi, Caribou, Pfizer
Research Funding: Pack Health
